UK Markets open in 7 hrs 36 mins

Novo Nordisk A/S (NOVO-B.CO)

Copenhagen - Copenhagen Real-time price. Currency in DKK
Add to watchlist
570.90+10.40 (+1.86%)
At close: 4:59PM CEST
Full screen
Previous close560.50
Open555.20
Bid571.10 x 0
Ask570.90 x 0
Day's range555.20 - 571.40
52-week range400.20 - 571.40
Volume1,485,009
Avg. volume1,854,581
Market cap1.311T
Beta (5Y monthly)0.32
PE ratio (TTM)31.03
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield9.10 (1.73%)
Ex-dividend date26 Mar 2021
1y target estN/A
  • Motley Fool

    Why Is Novo Nordisk Buying a Rare-Disease Candidate?

    Novo Nordisk (NYSE: NVO) recently announced that it's buying Prothena's (NASDAQ: PRTA) transthetyrin amyloidosis (ATTR) cardiomyopathy program for up to $1.2 billion. In this Motley Fool Live video recorded on July 14, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss why Novo, which is best known for its diabetes franchise, is buying a rare-disease drug candidate. There is a company, I don't know that we've talked about much, if at all in the past, Brian, Novo Nordisk.

  • Pharma Stock Roundup: NVO & LLY's Small Acquisitions, JNJ's Sunscreens Recall
    Zacks

    Pharma Stock Roundup: NVO & LLY's Small Acquisitions, JNJ's Sunscreens Recall

    Novo Nordisk (NVO) and Eli Lilly (LLY) announce small acquisition deals. J&J (JNJ) recalls some consumer products.

  • Prothena (PRTA) to Sell ATTR Amyloidosis Program to Novo Nordisk
    Zacks

    Prothena (PRTA) to Sell ATTR Amyloidosis Program to Novo Nordisk

    Prothena (PRTA) announces an agreement to sell its clinical-stage antibody, PRX004, and the broader ATTR amyloidosis program for $1.2 billion to Novo Nordisk.